Pharmaceutical businesses would rather EU policymakers get legislative reforms right than rush through imperfect changes that will have a long-term negative impact on industry, an expert in life sciences regulation has said.
We use cookies that are essential for our site to work. To improve our website, we would like to use additional cookies to help us understand how visitors use the site, measure traffic to our site from social media platforms and to personalise your experience. Some of the cookies that we use are provided by third parties. Please visit our Cookie Policy for more information. To accept all cookies click 'Accept all'. To reject all optional cookies or choose which optional cookies to allow, click ‘Cookie settings’. This tool uses a cookie to remember your choices.
See our Cookie Policy for more information
We are processing your request. \n Thank you for your patience.An error occurred. This could be due to inactivity on the page - please try again.